Adaptive Biotechnologies (ADPT) Cash from Investing Activities (2018 - 2026)

Adaptive Biotechnologies has reported Cash from Investing Activities for 9 years, with the latest figure at $9.1 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 64.25% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.5 million (down 63.44% YoY) and the FY2025 annual result came in at $37.9 million, down 51.22% from the prior year.
• Cash from Investing Activities climbed to $9.1 million in Q1 2026 per ADPT's latest filing, from -$8.3 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $63.0 million in Q1 2023 and troughed at -$97.5 million in Q4 2022.
• A 5-year average of $15.1 million and a median of $17.3 million in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities sank 245.13% in 2022, then soared 686.41% in 2023.
• Over 5 years, Cash from Investing Activities stood at -$97.5 million in 2022, then soared by 103.29% to $3.2 million in 2023, then surged by 589.71% to $22.1 million in 2024, then slumped by 137.31% to -$8.3 million in 2025, then surged by 210.8% to $9.1 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $9.1 million, -$8.3 million, and $17.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.